Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases

Clinical Rheumatology

Volumn 31, Issue 6, 2012, Pages 931-936

  Ryu, Han Hee ^a   Lee, Eun Young ^a   Shin, Kichul ^a   Choi, In Ah ^a   Lee, Yun Jong ^b   Yoo, Bin ^c   Park, Min Chan ^d   Park, Yong Beom ^d   Bae, Sang Cheol ^e   Yoo, Wan Hee ^f   Kim, Sung Il ^g   Lee, Eun Bong ^a   Song, Yeong Wook ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Chonbuk National University Medical School   (South Korea)

^g Pusan National University Hospital   (South Korea)

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor therapy; Hepatitis B virus; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA POLYMERASE; ENTECAVIR; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN MOTIF; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOUTH KOREA; VIRUS REACTIVATION;

ADULT; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84863716498     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-1960-1     Document Type: Article

References (28)

1. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK et al (2009) Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 9:67-81
2. Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
3. Gupta S, Govindarajan S, Fong TL et al (1990) Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 12:562-568
4. Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009-1022
5. Esteve M, Saro C, Gonzalez-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53:1363-1365
6. Sakellariou GT, Chatzigiannis I (2007) Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26:950-952
7. Carroll MB, Bond MI (2008) Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38:208-217
8. Ojiro K, Naganuma M, Ebinuma H et al (2008) Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 43:397-401
9. Chung SJ, Kim JK, Park MC et al (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36:2416-2420
10. Kim YJ, Bae SC, Sung YK et al (2010) Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 37:346-350
11. Lan JL, Chen YM, Hsieh TYet al (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibodypositive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70:1719-1725
12. Tamori A, Koike T, Goto H et al (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46:556-564
13. Ganem D, Prince AM (2004) Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350:1118-1129
14. Guidotti LG, Ishikawa T, Hobbs MV et al (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36
15. Guidotti LG, Ando K, Hobbs MV et al (1994) Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 91:3764-3768
16. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
17. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
18. Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49: S156-S165
19. Korea Centers for Disease Control and Prevention (2007) The Fourth Korea National Health and Nutrition Examination Survey (KNHANES III), pp 70-71
20. Kuwabara H, Fukuda A, Tsuda Yet al (2010) Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol
21. Michel M, Duvoux C, Hezode C et al (2003) Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 30:1624-1625
22. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359:1486-1500
23. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Annals Rheum Dis 69:1352-1355
24. Colonno RJ, Rose R, Baldick CJ et al (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656-1665
25. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507-539
26. Kim ES, Seoh YS, Lee KG et al (2008) Hepatitis B virus DNA level is a significant predictive factor for hepatitis B virus reactivation in inactive HBs antigen carriers. Korean J Hepatol 14:88
27. Liaw YF (1998) Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13:14-20
28. Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21:1366-1371